Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for NNVC.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2006. Start Trial.
Date Value
March 31, 2026 9.154M
December 31, 2025 11.07M
September 30, 2025 7.175M
June 30, 2025 7.518M
March 31, 2025 8.833M
December 31, 2024 10.39M
September 30, 2024 10.11M
June 30, 2024 11.46M
March 31, 2024 10.65M
December 31, 2023 12.45M
September 30, 2023 12.97M
June 30, 2023 14.87M
March 31, 2023 18.23M
December 31, 2022 19.87M
September 30, 2022 21.56M
June 30, 2022 23.08M
March 31, 2022 24.76M
December 31, 2021 26.47M
September 30, 2021 28.31M
June 30, 2021 29.91M
March 31, 2021 31.89M
December 31, 2020 27.75M
September 30, 2020 29.98M
June 30, 2020 21.76M
March 31, 2020 14.31M
Date Value
December 31, 2019 7.722M
September 30, 2019 9.130M
June 30, 2019 10.60M
March 31, 2019 12.72M
December 31, 2018 13.84M
September 30, 2018 15.98M
June 30, 2018 17.66M
March 31, 2018 19.15M
December 31, 2017 15.92M
September 30, 2017 18.52M
June 30, 2017 20.32M
March 31, 2017 22.41M
December 31, 2016 19.15M
September 30, 2016 20.23M
June 30, 2016 23.05M
March 31, 2016 23.98M
December 31, 2015 28.38M
September 30, 2015 30.71M
June 30, 2015 31.79M
March 31, 2015 31.86M
December 31, 2014 30.51M
September 30, 2014 36.83M
June 30, 2014 23.37M
March 31, 2014 32.03M
December 31, 2013 10.21M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 1.307B
Alnylam Pharmaceuticals, Inc. 1.354B
Anika Therapeutics, Inc. 137.28M
Savara, Inc. 143.66M
Vericel Corp. 370.04M

Shareholders Equity (Quarterly) Related Metrics